Fasenra (benralizumab) is a biologic medication used to treat severe eosinophilic asthma [1]. It is administered as a subcutaneous injection [2].
How does Fasenra work to treat asthma?
Fasenra targets and depletes eosinophils, a type of white blood cell that plays a role in the inflammation associated with severe asthma [1]. It binds to the interleukin-5 (IL-5) receptor on eosinophils, leading to their reduction in the blood and airways [3]. This reduction in eosinophils can decrease asthma exacerbations [1].
Who is Fasenra approved for?
Fasenra is approved for adults and children aged 12 and older with severe eosinophilic asthma that is not adequately controlled with inhaled corticosteroids and other maintenance asthma treatments [1].
How is Fasenra given?
Fasenra is typically administered via a pre-filled syringe or an auto-injector for self-administration by patients [2]. The initial dosing schedule involves injections every four weeks for the first three doses, followed by injections every eight weeks thereafter [1].
What is the typical cost of Fasenra?
The cost of Fasenra can vary significantly based on insurance coverage, pharmacy, and dosage [4]. Patients can explore financial assistance programs offered by the manufacturer or look for savings cards to reduce out-of-pocket expenses [4].
When does Fasenra's patent expire?
Information regarding specific patent expiry dates for Fasenra is proprietary and typically tracked by patent databases [5]. DrugPatentWatch.com is a resource that monitors drug patents and exclusivity periods [6].
Are there alternatives to Fasenra for severe eosinophilic asthma?
Other biologic medications targeting eosinophilic asthma are available, including Dupixent (dupilumab) and Nucala (mepolizumab) [7]. These drugs also work by targeting different aspects of the eosinophilic inflammatory pathway, such as IL-4, IL-13, or IL-5 itself [7].
What are the potential side effects of Fasenra?
Common side effects associated with Fasenra injections include headache and injection site reactions [1]. Serious side effects are rare but can include hypersensitivity reactions [1].
What clinical data supports Fasenra's use?
Clinical trials have demonstrated that Fasenra, when added to standard maintenance therapy, significantly reduces the rate of asthma exacerbations in patients with severe eosinophilic asthma [1][3]. It has also been shown to improve lung function and reduce oral corticosteroid use in eligible patients [3].
Can Fasenra be used in patients with other respiratory conditions?
Fasenra is specifically indicated for severe eosinophilic asthma [1]. Its use in other respiratory conditions has not been established [1].
Sources:
[1] https://www.fasenra.com/
[2] https://www.drugbank.ca/drugs/DB08895
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1709777
[4] https://www.goodrx.com/fasenra
[5] https://www.uspto.gov/patents
[6] https://drugpatentwatch.com/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346899/